{"pub": "axios", "url": "https://axios.com/johnson-johnson-legal-cases-risperdal-opioids-a3ffb0bd-6a0f-4a01-bc7f-ace181070f57.html", "downloaded_at": "2019-10-14 10:16:14.626657+00:00", "title": "Johnson & Johnson faces mounting litigation", "language": "en", "text": "Where it stands: A jury recently said J&J had to pay $8 billion to a man who claimed he got enlarged breasts from taking the company's antipsychotic drug Risperdal.\n\nAn Oklahoma judge ruled J&J has to pay $572 million for its role in creating the opioid crisis. Billions more could be on the line for the company in the 2,000 other opioids cases.\n\nJ&J paid $1 billion earlier this year to settle cases tied to defective metal hip implants.\n\nThe company is appealing a $4.7 billion verdict tied to claims that its talc powder caused cancer in women.\n\nA trial is underway in California over J&J's allegedly faulty pelvic mesh devices.\n\nThe Federal Trade Commission is investigating whether J&J's contracting practices for Remicade, a treatment for autoimmune and inflammatory diseases, violate federal antitrust laws.\n\nWhat we're watching: We'll likely know more about J&J's litigation costs when the company reports its third-quarter earnings this week.\n\nYes, but: Investors have not fled J&J, because it is the most profitable health care company in the country, collecting almost $9.4 billion of profit in the first half of this year.\n\nWhat they're saying: J&J submitted a statement that said its \"reputation remains strong,\" and when it comes to its legal cases, \"the facts in these cases are on our side.\"", "description": "J&J has spent $900 million on legal expenses thus far.", "authors": [], "top_image": "https://images.axios.com/DuKr2pd1SuLjWmldlK1HhAlO7VE=/0x0:1920x1080/1920x1080/2019/10/11/1570820319205.jpg", "published_at": "2019-10-14"}